Claims for Patent: 9,205,048

Summary for Patent: 9,205,048

Title:	Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Abstract:	Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s):	Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA)
Assignee:	OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:	14/618,926
Patent Claims:	1. A method of treating middle ear effusion in a pediatric patient with otitis media undergoing tympanostomy tube placement, the method comprising intratympanically administering to the pediatric patient a composition comprising poloxamer 407 and a therapeutically effective amount of multiparticulate and non-microencapsulated ciprofloxacin, wherein the composition provides a sustained release of ciprofloxacin in the ear for a period of at least 5 days after a single intratympanic administration; and wherein the composition comprises from about 10 wt % to about 20 wt % poloxamer 407. 2. The method of claim 1, wherein the composition comprises from about 14 wt % to about 18 wt % poloxamer 407. 3. The method of claim 1, wherein the composition comprises from about 15 wt % to about 17 wt % poloxamer 407. 4. The method of claim 1, wherein the composition comprises about 16 wt % poloxamer 407. 5. The method of claim 1, wherein the multiparticulate ciprofloxacin is essentially in the form of micronized particles. 6. The method of claim 1, wherein the composition provides a sustained release of ciprofloxacin in the ear for a period of at least 10 days after a single intratympanic administration. 7. The method of claim 1, wherein the composition provides a sustained release of ciprofloxacin in the ear for a period of at least 14 days after a single intratympanic administration. 8. The method of claim 1, wherein the pediatric patient is from 6 months to 12 years old. 9. A method of treating middle ear effusion in a pediatric patient with otitis media undergoing tympanostomy tube placement, the method comprising intratympanically administering to the pediatric patient a composition comprising from about 15 wt % to about 17 wt % of poloxamer 407 and a therapeutically effective amount of micronized and non-microencapsulated ciprofloxacin, wherein the pediatric patient is from 6 months to 12 years old, and wherein the composition provides a sustained release of ciprofloxacin in the ear for a period of at least 5 days after a single intratympanic administration. 10. The method of claim 9, wherein the composition provides a sustained release of ciprofloxacin in the ear for a period of at least 10 days after a single intratympanic administration. 11. The method of claim 9, wherein the composition provides a sustained release of ciprofloxacin in the ear for a period of at least 14 days after a single intratympanic administration.